Why the study?
The study was conducted to analyze the connection between adiponectin, hs-CRP, hs-Troponin T, and lipid biomarkers during the early phase of acute STEMI.
Are adiponectin levels altered in the early phase of acute STEMI compared to unstable angina?
Are adiponectin levels altered in the early phase of acute STEMI compared to unstable angina?
Adiponectin plasma concentrations are diminished during the first hours of STEMI, supporting its potential anti-inflammatory and anti-atherogenic features.
Lower adiponectin in early STEMI versus unstable angina may mark acute inflammation; leaves open prognostic or therapeutic implications.
Adiponectin is secreted by fatty tissue; it has a peptide biochemical structure and among other roles, it seems to inhibit endothelial inflammation. C-reactive protein has an essential role in host defense. Troponin is a protein that is part of cardiac and skeletal muscle contraction. Myocardial infarction is an acute event defined as myocardial cell necrosis, caused by sudden and sustained ischemia. The purpose of our search work was to analyze the connection between various biomarkers over the early phase of acute STEMI: adiponectin, high sensitive-C reactive protein (hs-CRP), high sensitive-Troponin T (hs-Troponin T), triglycerides, total -, LDL- and HDL-cholesterol. Our study included two groups of patients - one group of 30 patients diagnosed with STEMI in the first 12 h after onset, and the second group of 30 patients with unstable angina pectoris, normal hs-Troponin T, and normal findings at coronary angiography computed tomography (CT). Subjects in the STEMI-arm had a higher serum level of hs-CRP, hs-Troponin T, total cholesterol, LDL cholesterol, triglycerides, and decreased levels of HDL-cholesterol and adiponectin than those in the angina-arm. We identified diminished adiponectin plasma concentrations during the first hours of STEMI evolution. We also found out a directly proportional ratio among adiponectin and HDL-cholesterol and an inverse report between this hormone and all other studied biomarkers. Our results may support the anti-inflammatory and anti-atherogenic features of adiponectin.
No takes yet. Share an insight, caveat, or question.
Parepa et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: